Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

ARTV vs ATYR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ATYR Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 2–4 Matrix Metrics)

ATYR Overall Winner 6-Pillar Tally: ARTV 1 – 3 ATYR (2 Tie) Matrix Metrics: ARTV 4 – 2 ATYR

As of Nov 17, 2026, aTyr Pharma, Inc. (ATYR) is the stronger overall head-to-head candidate over Artiva Biotherapeutics, Inc. (ARTV) in the Tradestie Institutional Equity Comparison Engine, winning 2–4 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, Options & Positioning). ARTV carries a Unified Composite Score of 48.5/100 (HOLD) at $3.85 (N/M Forward P/E, 0.0% operating margin), whereas ATYR carries 34.3/100 (SELL) at $4.83 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While ARTV currently prints a higher short-term Unified Composite Score (48.5/100 HOLD vs. ATYR 34.3/100 SELL), ATYR captures the overall institutional head-to-head verdict (2–4 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. -100.0% YoY).
  • Technical & Structure Timing Caution: ARTV is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 20.8); meanwhile ATYR trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 57.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ARTV vs ATYR
ARTV NASDAQ
Artiva Biotherapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$3.85
-2.65% 1D
Market Cap $198.2M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.74β · 114% Vol
Unified Composite Score
48.5 / 100 HOLD
Tech 50.0 Fund 60.0 Flow 64.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -30.1%), weak momentum, RSI 21
RSI-14: 20.8 · SMA20: $4.55 · SMA50: $6.37
ATYR NASDAQ Head-to-Head Winner
aTyr Pharma, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$4.83
-7.82% 1D
Market Cap $15.6M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -9.57β · 13806% Vol
Unified Composite Score
34.3 / 100 SELL
Tech 50.0 Fund 36.0 Flow 69.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (391.4% over 20 days), RSI 58
RSI-14: 57.6 · SMA20: $4.36 · SMA50: $1.92

6-Pillar Scorecard Institutional Category Breakdown (ARTV 1 – 3 ATYR)

Columns: Metric · ARTV · ATYR
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale ATYR
Revenue Growth (YoY) -100.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A N/A
Market Cap $198.2M $15.6M
3. Profitability & Quality ARTV
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -43.6% -93.7%
4. Balance Sheet & Cash Flow ATYR
Cash Generation (TTM) -$87M N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $52M Net Cash $4.9M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ATYR
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 53.6% (<1st %ile) 154.5% (36th %ile)
Put/Call OI Skew 0.23x (Call-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ARTV (4) vs ATYR (2)
Institutional Metric ARTV ATYR Criterion Row Edge
Market Capitalization
Scale
$198.2M $15.6M Larger Scale ARTV
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-100.0% +0.0% Higher Growth ATYR
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-43.6% -93.7% Higher ROE ARTV
52-Week Range Position
Momentum
7% ($3–$15) 60% ($0–$8) Stronger Trend ATYR
Beta / 30D Volatility
Risk Regime
1.74β · 114% Vol -9.57β · 13806% Vol Lower Realized Risk ARTV
Unified Institutional Score
Composite Signal
48.5 / 100 (HOLD) 34.3 / 100 (SELL) Higher Composite ARTV
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$87M ($52M Net Cash) N/A ($4.9M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ATYR +2747.6 pp
ARTV: -34.55% · ATYR: +2713.05%
3M Horizon ATYR +873.58 pp
ARTV: -67.05% · ATYR: +806.53%
6M Horizon ATYR +954.91 pp
ARTV: -54.91% · ATYR: +900.0%
1Y Horizon ATYR +522.81 pp
ARTV: +18.62% · ATYR: +541.43%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ARTV Revenue ATYR Revenue ARTV Op. Margin ATYR Op. Margin Margin Leader
FY2019 N/A $0M N/A -5445.0% ATYR
FY2020 N/A $10M N/A -152.2% ATYR
FY2022 N/A $10M N/A -446.8% ATYR
FY2023 $30M $0M -93.2% -15557.8% ARTV
FY2024 $0M $0M -26805.6% -28899.6% ARTV
FY2025 N/A $0M N/A -40856.3% ATYR

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ARTV BREAKDOWN
147d in phase · OBV NEUTRAL
Current IV 53.6%
IV Percentile <1st %ile
Put/Call OI Skew 0.23x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ARTV Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ATYR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 154.5%
IV Percentile 36th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ATYR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ARTV Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $198.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ATYR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $15.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ARTV vs ATYR Key Questions & Quantitative Answers

As of Nov 17, 2026, aTyr Pharma, Inc. (ATYR) is the stronger overall head-to-head candidate over Artiva Biotherapeutics, Inc. (ARTV) in the Tradestie Institutional Equity Comparison Engine, winning 2–4 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, Options & Positioning). ARTV carries a Unified Composite Score of 48.5/100 (HOLD) at $3.85 (N/M Forward P/E, 0.0% operating margin), whereas ATYR carries 34.3/100 (SELL) at $4.83 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While ARTV currently prints a higher short-term Unified Composite Score (48.5/100 HOLD vs. ATYR 34.3/100 SELL), ATYR captures the overall institutional head-to-head verdict (2–4 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. -100.0% YoY). Technical & Structure Timing Caution: ARTV is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 20.8); meanwhile ATYR trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 57.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ATYR leads the Growth & Scale pillar: ARTV posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ATYR at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 6-period historical trajectory (FY2019 to FY2025), ARTV cumulative revenue shifted N/A while ATYR shifted +0.0%. In operating R&D and SG&A reinvestment, ARTV deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ATYR.

ARTV and ATYR trade at balanced relative valuation multiples. ARTV trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas ATYR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ARTV (-43.6% ROE) versus ATYR (-93.7% ROE) capital efficiency.

In options market volatility and institutional positioning, ARTV carries 53.6% implied volatility (<1st %ile, Compressed (<25th %ile)), a 0.23x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.74β · 114% Vol realized risk). By comparison, ATYR carries 154.5% implied volatility (36th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-9.57β · 13806% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.